RxDoctor Payments DataLook up a doctor →

Paul Feuerstadt, MD

Gastroenterology · Hamden, CTNPI 1386975928

Payments from drug & device makers

$1,392,718in general payments, 2019–2025

Across 877 payments — averaging $1588.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ferring Pharmaceuticals Inc.$399K
  • Sanofi$221K
  • Regeneron Healthcare Solutions, Inc.$132K
  • Aimmune Therapeutics, Inc.$85K
  • Bristol Myers Squibb$84K
  • Rebiotix Inc.$81K
  • plus $391K from 36 others

What the payments were for

  • Consulting fees$439,99143%
  • Speaking & faculty fees$520,69250%
  • Travel & lodging$58,5506%
  • Food & beverage$14,2011%
  • Education$1,2400%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,392,718 in reported general payments places this provider in the 95th percentile of 326 gastroenterology providers in Connecticut.

See all gastroenterology providers in Connecticut

Medicare billing

Part B allowed, 2024
$79,627
Medicare patients
213
Services billed
1,752

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab22$183,064
LinzessLinaclotide52$29,317
CreonLipase/Protease/Amylase17$28,308
Mesalamine11$12,409
DexilantDexlansoprazole12$7,278
Dexlansoprazole DrDexlansoprazole28$6,758
SutabSod Sulf/Pot Chloride/Mag Sulf36$5,885
Pantoprazole Sodium292$4,313
Vancomycin Hcl21$3,460
Sucralfate14$2,980
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates41$2,526
Omeprazole106$1,643
Dicyclomine Hcl68$1,335
Famotidine84$1,133
Esomeprazole Magnesium31$952

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$80,794$57,62469 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$40,404$7,27812 claims
Braintree Laboratories, Inc.Sutab$51$5,88536 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 326 gastroenterology providers in Connecticut.

Other gastroenterology in Hamden

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →